The fecal levels of short-chain fatty acid (SCFA) and serum inflammatory markers.
Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda – Biotech Investments
EQS-News: Formycon AG / Key word(s): Study/Miscellaneous Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda 13.06.2024 / 07:31